자보플록사신

자보플록사신
자보플록사신 구조식 이미지
카스 번호:
219680-11-2
한글명:
자보플록사신
동의어(한글):
자보플록사신
상품명:
Zabofloxacin
동의어(영문):
Zabofloxacin;DW-224a Free base;1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-4-oxo-
CBNumber:
CB91508625
분자식:
C19H20FN5O4
포뮬러 무게:
401.39
MOL 파일:
219680-11-2.mol

자보플록사신 속성

저장 조건
Store at -20°C
용해도
DMSO에 용해됨
물리적 상태
Solid
색상
White to off-white

안전

자보플록사신 C화학적 특성, 용도, 생산

개요

Zabofloxacin is a quinolone antibiotic originally developed by Dong Wha Pharmaceuticals and licensed to Pacific Beach Biosciences in 2007. In March 2015, Korea’s Ministry of Food and Drug Safety (MFDS) approved zabofloxacin for the treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABE-COPD). In 2016, zabofloxacin gained approval from the USFDA for the treatment of community-acquired pneumonia. ABE-COPD is caused by respiratory tract and pulmonary parenchyma that cause chronic pulmonary inflammation and obstruction in the respiratory tract, which leads to irreversible damage. In the nonclinical evaluation process, zabofloxacin showed strong antibiotic activity on respiratory germs (e.g., Streptococcus pneumonia, S. Haemophilus, S. moraxella) and was the most potent antibacterial agent against penicillin-resistant S. pneumoniae (PRSP) in the murine systemic infection model.

Synthesis

The synthesis of zabofloxacin leverages the wide commercial availability of chloronaphthyridinone acid 106 to essentially reduce the task to the construction of functionalized diazaspirocyclic pyrrolidine 105. As described in a series of patents from researchers at Dong Wha who have exemplified the synthesis on multikilogram scale, the route began with first converting the commercially available ketone 100 to the corresponding oxime followed by formylation to give oximyl alcohol 101. Next, mesylation of the alcohol was followed by conversion of the nitrile to the corresponding amine 103. An intramolecular ring closing step then occurred to secure the azetidine using aqueous sodium hydroxide. Salt formation with phthalic acid furnished 104 in good yield. Next, Boc-protection of the azetidine followed by hydrogenative Cbz removal and treatment with succinic acid resulted in the formation of amine salt 105, and this was followed by a substitution reaction with 106 to deliver the Boc-protected zabofloxacin structure 107. Lastly, removal of Boc via TFA followed by basification and subjection to D-aspartate in warm ethanol furnished zabofloxacin D-aspartate (VIII) in 56% yield for the three-step sequence.

Synthesis_219680-11-2

자보플록사신 준비 용품 및 원자재

원자재

준비 용품


자보플록사신 공급 업체

글로벌( 9)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21667 55
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
AFINE CHEMICALS LIMITED
+86-0571-85134551
info@afinechem.com China 15395 58
Jinan Yaoyan Pharmaceutical Co., Ltd.
jnyaoyan@163.com China 3069 58
Fan De(Beijing) Biotechnology Co., Ltd. 15911056312
liming@bio-fount.com China 9730 58
Nanjing Meihao Pharmaceutical Technology Co., Ltd. meitaochem@126.com
meitaochem@126.com China 19105 58
TargetMol Chemicals Inc. 4008200310
marketing@tsbiochem.com China 23960 58
RD International Technology Co., Limited 18024082417
market@ubiochem.com China 9268 58

Copyright 2019 © ChemicalBook. All rights reserved